High-level scientists & high-end laboratory equipment for the most relevant in vitro CNS studies

High-level scientists & high-end laboratory equipment for the most relevant in vitro CNS studies

Neuro-Sys is an innovative French Drug Discovery and Services company focusing on neurodegenerative diseases, such as :

Alzheimer’s disease (AD)
Parkinson’s disease (PD)
Huntington’s disease (HD)
Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease)
Multiple Sclerosis (MS)
Peripheral Neuropathies

Neuro-Sys has developed specific preclinical models of neurological diseases to accurately determine the pharmacological profiling of leads compounds and explore their underlying mechanism of action. All processes are standardized and automated.

Neuro-Sys also develops its proper drug discovery programs based on an innovative and unique approach.

With the support of its team of neuroscientists, pharmacists and its high level scientific board, Neuro-Sys is the priviligié partner of the pharmaceutical industry, biotech, start-ups and nutraceutical specialized companies to provide with innovative and promising active new compounds and preclinical services.

Scientific board

Poindron, PharmD, PhD
Chairman of the Board.

Dr. Poindron, Professor of Virology and Cell Biology at The Université de Strasbourg (formerly Université Louis Pasteur), has been one of the BioValley initiative promoters with Swiss and German colleagues. He especially worked on interferon, adoptive immunotherapy of cancer and neurodegenerative diseases, using modelled mixed cell culture.

Anton, PhD.

Emeritus of the University of Strasbourg (France), Dr. Robert ANTON is member of the national Academies of Medicine and Pharmacy and past member of the High Council of Public Health at the Ministry of Health in Paris. Specialized in the field of natural products, he was member of a lot of European panels and Committee of experts concerning drugs, cosmetics and food supplements. As example, he was expert at the ANSM (French Agency of Drug Safety), at the European Commission of Pharmacopoeia, but also Chairman at the Public Health Committee at the Council of Europe, at the SCCNFP (Scientific Committee on Cosmetics and Non Food Products) in Brussels and always is expert at EFSA (European Food Safety Authority).

Chemat, PhD.

Dr. Chemat, Professor of Chemistry at Avignon University (France), is Director of GREEN Extraction Team (alternative extraction techniques and solvents), co-director of ORTESA LabCom research unit Naturex-UAPV, and scientific coordinator of PEEV (Industrial platform for green extraction at Valréas). His main research interests are focused on innovative and sustainable extraction techniques, protocols and solvents (especially microwave, ultrasound and bio-based solvents) for food, pharmaceutical, fine chemistry, biofuel, and cosmetic applications.

Mariani, MD, PhD.

Dr. Mariani, Professor of Cell Biology and Biology of aging at the University Pierre & Marie Curie (UPMC) is also practicing at the Charles Foix Hospital (Public Assistance-Paris Hospitals, AP-HP). Since its establishment in 2001, he has run the Neurobiology of Adaptive Processes Laboratory (CNRS/UPMC) which conducts research concerning the nervous system’s late stages of development, its ageing and some of its neurodegenerative pathologies.

Mottier, PhD.

Pharmacist and MSc in formulation, process and production with 15 year in CMC (Chemistry, Manufacturing and Controls) development for the pharmaceutical industry. Worked for all size and form of company from small virtual company to big pharma and CDMO publically or privately owned or as CMC expert consultant. Experience in the sourcing or synthesis of numerous drug substance and development of a wide variety of formulations for project in all stage of development. As such, worked on numerous CMC sections of the regulatory applications for European countries, USA or Asian countries.

Ollivier, PhD.

Dr. Ollivier, Professor of Pharmacognosy, Phytochemistry, Phytotherapy and Etnopharmacology, is specialized in the discovery of bioactive molecules from plant biodiversity. She is a member of the Society of Medicinal Plant Research, the Association Française pour l’Enseignement et la Recherche en Pharmacognosie (AFERP) and the vice president of the French Society of Enthnopharmacology.

Stoclet, PharmD, PhD.

Dr. Stoclet, former professor of pharmacology at the Faculty of Pharmacy of Strasbourg, is an honorary member of the Académie Nationale de Pharmacie, a member of the French Pharmacology Society, the British Pharmacology Society and the American Pharmacology and Experimental Therapeutics Society.

Collaboration and partners

Strategic alliances have been setup with significant companies and institutions across the world to provide the most narrowly-targeted services and screening assays compliant with notably client needs.

Financial partners: